Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck Semiconductor ETF (SMH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

VanEck Semiconductor ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

VanEck Semiconductor ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? VanEck Semiconductor ETF trades at $584.89, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.

SMHVRTX
52-Week High
$668.91$529.65
52-Week Low
$286.43$376.62
Market Cap
$134.25B
Sector
Health
Enterprise Value
$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck Semiconductor ETF

SMH trades at $584.83, up 2.71% with a neutral technical signal. Moving averages show bullish momentum while oscillators indicate neutral conditions. Recent institutional activity includes Ferguson Shapiro's $4.53 million investment and Clark Asset Management's 105.8% stake increase. The ETF faces competition from alternative semiconductor funds like CHPY, which some analysts favor for income generation.

Outlook remains balanced with AI spending driving semiconductor demand but increasing competition and tariff risks. The fund's heavy Nvidia concentration presents both opportunity and volatility risk. Technical resistance at $587 could limit near-term gains while support at $560 provides downside protection.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.

Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck Semiconductor ETF

The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.

Read more on SMH

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX